Game-changing new treatment just arrived for one of the deadliest cancers

Key Points:

• Pancreatic cancer, the third-leading cause of cancer death in the US with a five-year survival rate of just 13%, has a new FDA-approved treatment called Rasonque (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic adenocarcinoma.
• Daraxonrasib is an oral drug that inhibits multiple forms of the RAS protein, which is abnormally activated in over 90% of pancreatic adenocarcinomas, and clinical trials showed it nearly doubled median overall survival compared to chemotherapy (13.2 vs. 6.7 months).
• Despite this advancement, daraxonrasib is not a cure as most patients eventually develop resistance; researchers hope it will lead to additional therapies and combinations that improve outcomes and extend benefits to earlier-stage disease.
• Early detection remains a major challenge due to the pancreas's deep location and late symptom onset; ongoing research focuses on blood tests, advanced imaging, and AI to identify cancer earlier and improve surgical options.
• Future pancreatic cancer treatments are exploring immunotherapy approaches, though breakthroughs comparable to other cancers have yet to be achieved, with efforts focused on making tumors more vulnerable to immune attack.